eBulletin Newsletter

NCCN Flash Updates: NCCN Guidelines and NCCN Templates Updated for Breast Cancer

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium^®) for Breast Cancer. These NCCN Guidelines^® are currently available as Version 5.2023.

Link directly to the Updates section of the NCCN Guidelines: Breast Cancer

Terminologies in all NCCN Guidelines are being actively modified to advance the goals of equity, inclusion, and representation. 

BINV-P

• HER2-Negative and postmenopausal or premenopausal receiving ovarian ablation or suppression, Second- and Subsequent-Line Therapy, Preferred Regimens,
  • Revised: For PIK3CA-mutated tumors or AKT1/PTEN-activating mutations, see additional targeted therapy options, see BINV-Q (6).

BINV-Q (6 of 14)

• Table for biomarkers associated with FDA-approved therapies, For patients with HR+/HER-negative tumors with PIK3CA/AKT1/PTEN activating mutations added: Capivasertib + fulvestrant as a category 1 preferred regimen. With footnote x: In adult patients with PIK3CA/AKT1/PTEN activating mutations after disease progression or recurrence after one or more prior lines of endocrine therapy, including one line containing a CDK4/6 inhibitor.

BINV-Q (13 of 14)

• Additional targeted therapies and associated biomarker testing for recurrent unresectable (local or regional) or stage IV (M1) disease: Dosing added for capivasertib + fulvestrant.

BINV-Q (14 of 14)

• Reference 2 added: Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor–positive advanced breast cancer. N Engl J Med 2023; 388:2058-2070.

Previous updates to the NCCN Guidelines for Breast Cancer can be found in the UPDATES section of the current version.

NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates^®) for Breast Cancer to reflect the currently published NCCN Guidelines for Breast Cancer v5.2023.

• The following New NCCN Template^® has been published:
  •  BRS193: Capivasertib + Fulvestrant

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients^®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium^®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Third Party Content: The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content site: https://private.filesanywhere.com/fs/v.aspx?v=8a6d65cfa19ea4bda0a3&C=6241. Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works. 

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.